FLT3 and acute myeloid leukemia: The clinical use of small-molecule inhibitors of FLT3 signaling has in general been disappointing in AML (Kayser and Levis, 2014), with frequent acquisition of resistance causing mutations in patients demonstrating an initial response (Smith et al., 2012).